Respiratory Viral Infections Following CAR-T Cell Therapy for Lymphoma and Myeloma: Severity and Immune Correlates.
Identifying low immune cell counts after CAR-T therapy could help clinicians predict and prevent serious respiratory infections in cancer patients.
BACKGROUND: Infectious complications are a major cause of morbidity and non-relapse mortality after CAR-T cell therapy. Impaired immune reconstitution, particularly lymphopenia, is associated with increased risk, with an ALC <0.5 × 10⁹/L emerging as a clinically relevant threshold.
What the study was
- Study design
- Retrospective cohort study
- Population
- Commercial CAR-T recipients for lymphoma and myeloma (n=563, 2018-2024)
- Sample size
- 563
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Why it surfaced
Large retrospective characterization of respiratory viral infections in CAR-T recipients provides clinically actionable data on infectious morbidity and immune reconstitution patterns.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.